＜論文＞
(IF, Impact Factor)

2024年

  1. Saito T, Kurokawa Y, Fujitani K, Kawabata R, Takeno A, Mikami J, Endo S, Matsuyama J, Akamaru Y, Hirota M, Kishi K, Urakawa S, Yamamoto K, Tanaka K, Takahashi T, Oka M, Wada H, Eguchi H, Doki Y, Osaka University Clinical Research Group for Gastroenterological Study. Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer: a multicenter prospective observational study. British Journal of Cancer 2024 (in press) (IF = 8.8)
2023年

  1. Kurose K, Sakaeda K, Fukuda M, Sakai Y, Yamaguchi H, Takemoto S, Shimizu K, Masuda T, Nakatomi K, Kawase S, Tanaka R, Suetsugu T, Mizuno K, Hasegawa T, Atarashi Y, Irino Y, Sato T, Inoue H, Hattori N, Kanda E, Nakata M, Mukae H, Oga T, Oka M. Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers. Advances in Clinical Chemistry 112:155-204, 2023 (Review Article) (IF = 6.303) doi:10.1016/bs.acc.2022.09.004
  2. Tanahashi H, Yamaguchi K, Kurose K, Nakao S, Sakamoto S, Horimasu Y, Masuda T, Miyamoto S, Nakashima T, Iwamoto H, Fujitaka K, Hamada H, Oga T, Oka M, Hattori N. The predictive value of serum High-mobility group box 1 levels for checkpoint inhibitor pneumonitis. Respirology 28(4):380-388, 2023 (IF = 6.9)
    doi.org/10.1111/resp.14425
  3. Fujikawa K, Saito T, Kurose K, Kojima T, Funakoshi T, Sato E, Kakimi K, Iida S, Doki Y, Oka M, Ueda R, Wada H. Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors. PLos One 18(9):e0291772, 2023 (IF = 3.7) doi:10.1371/journal.pone.0291772
2022年

  1. Okamoto S, Miyano K, Choshi T, Sugisawa N, Nishiyama T, Kotouge R, Yamamura M, Sakaguchi M, Kinoshira R, Tomonobu N, Katase N, Sasaki K, Nishina S, Hino K, Kurose K, Oka M, Kubota H, Ueno T, Hirai T, Fujiwara H, Kawai C, Itadani M, Morihara A, Matsushima K, Kanegasaki S, Hoffmann RM, Yamauchi A, Kuribayashi F. A chemotaxis inhibiting agent identified in vitro with TAXIScan, a real-time cell mobility assay device, inhibits pancreas cancer growth and metastasis in orthotropic and subcutaneous mouse models. Biomedicine & Pharmacotherapy 155:113733, 2022 (IF = 7.419) doi: 10.1016/j.biopha.2022.113733
2021年

  1. Sakai Y, Kurose K, Sakaeda K, Abo H, Atarashi Y, Ide N, Sato T, Kanda E, Fukuda M, Oga T, Noda K, Oka M. A novel automated immunoassay for serum NY-ESO-1 and XAGE1 antibodies in combinatory prediction of response to anti-programmed cell death-1 therapy in non-small-cell lung cancer. Clinica Chimica Acta 519(8): 51-59, 2021. (IF = 6.314)
    https://doi.org/10.1016/j.cca.2021.04.008
    Application Sheet: https://ruo-products.sysmex.co.jp/news/2021/03_211207.html
  2. Maeda Y, Wada H, Sugiyama D, Saito T, Irie T, Itahashi K, Minoura K, Suzuki S, Kojima T, Kakimi K, Nakajima J, Funakoshi T, Iida S, Oka M, Shimamura T, Doi T, Doki Y, Nakayama E, Ueda R, Nishikawa H. Depletion of central memory CD8+ T cells might impede the antitumor therapeutic effect of Mogamulizumab. Nature Communications 12:7280, Published 14 December, 2021
    (IF = 17.694) https://doi.org/10.1038/s41467-021-27574-0
  3. Nojima Y, Shimizu K, Saisho S, Maeda A, Kurosaki T, Kurose K, Oga T, Oka M, Nakata M. Tumor PD-L1 and VEGF expression, and CD8 T cell infiltration predict clinical responses to immune checkpoint inhibitors in non-small cell lung cancer. Anticancer Res 41:5469-5475, 2021 (IF = 2.435)
    doi: 10.21873/anticanres.15359
  4. Saito T, Kurose K, Kojima T, Funakoshi T, Sato E, Nishikawa H, Nakajima J, Seto Y, Kakimi K, Iida S, Doki Y, Oka M, Ueda R, Wada H. Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors. Nagoya Journal of Medical Science 83(4):827-840, 2021 (IF = 0.762) doi:10. 18999/nagjms.83.4.827
2020年

  1. Yasogawa N, Shirai R, Tanaka H, Kurose K, Oga T, Oka M. Thoracoscopic findings in IgG4-related pleuritis. Internal Medicine 59(2):257-260, 2020. (IF = 1,271)
    doi: 10.2169/internalmedicine.3031-19
2019年

  1. Ohue Y, Kurose K, Karasaki T, Isobe M, Yamaoka T, Futami J, Irei I, Masuda T, Fukuda Ma, Kinoshita A, Matsushita H, Shimizu K, Nakata M, Hattori N, Yamaguchi H, Fukuda Mi, Nozawa R, Kakimi K, Oka M. Serum antibody against NY-ESO-1 and XAGE1 antigens potentially predicts clinical responses to anti-programmed cell death-1 therapy in NSCLC.
    Journal of Thoracic Oncology 14(12):2071-2083, 2019
    doi: https://doi.org/10.1016/j.jtho.2019.08.008. (IF = 20.121)
2018年

  1. Ikeda M, Katoh S, Oka M. A recurrent case of eosinophilic pneumonia with high IL-25 levels. Allergology International 67S:S38-S40, 2018 Sep. doi: 10.1016/j.alit.2018.03.005. (IF = 5.836)
  2. Katoh S, Ikeda M, Shirai R, Abe M, Ohue Y, Kobashi Y, Oka M. Biomarkers for differentiation of patients with asthma and chronic obstructive pulmonary disease. Journal of Asthma 55(10):1052-1058, 2018. Doi 10.1080/02770903.2017.1391281. (IF = 2.515)
  3. Okita R, Nojima Y, Saisho S, Shimizu K, Shirai R, Kanomata N, Oka M, Nakata M. AME Case Reports 4;2:43, 2018 Oct. doi: 10.21037/acr.2018.09.02. eCollection 2018.
2017年

  1. Ikeda M, Katoh S, Shimizu H, Hasegawa A, Ohashi-Doi K, Oka M. Beneficial effects of Galectin-9 on allergen-specific sublingual immumotherapy in a Dermatophagoides farinae-induced mouse model of chronic asthma. Allergology International 66(3):432-439, 2017 Jul. doi: 10.1016/j.alit.2016.10.007. (IF = 5.836)
  2. Katoh S, Ikeda M, Matsumoto N, Shimizu H, Abe M, Ohue Y, Mouri K, Nakazato M, Oka M. Possible role of IL-25 in eosinophilic lung inflammation in patients with chronic eosinophilic pneumonia. Lung 195(6):707-712, 2017 Dec. doi: 10.1007/s00408-017-0048-8. (IF = 2.584)
  3. Takeoka T, Nagase H, Kurose K, Ohue Y, Yamasaki M, Takiguchi S, Sato E, Isobe M, Kanazawa T, Matsumoto M, Iwahori K, Kawashima A, Morimoto-Okazawa A, Nishikawa H, Oka M, Pan L, Venhaus R, Nakayama E, Mori M, Doki Y, Wada H. NY-ESO-1 protein cancer vaccine with Poly-ICLC and OK-432 ~ Rapid and strong induction of NY-ESO-1 specific immune responses by Poly-ICLC. Journal of Immunotherapy 40(4):140-147, 2017 May. doi: 10.1097/CJI.0000000000000162. [Epub ahead of print] (IF = 4.110)
2016年

  1. Ohue Y, Kurose K, Nozawa R, Isobe M, Nishio Y, Tanaka T, Doki Y, Hori T, Fukuoka J, Oka M, Nakayama E. Survival of lung adenocarcinoma patients predicted from expression of PD-L1, Galectin-9, and XAGE1 (GAGED2a) on tumor cells and tumor-infiltrating T cells. Cancer Immunology Research 4(12):1049-1060, 2016 (IF = 11.151)
  2. Kobashi Y, Mouri K, Kato S, Oka M. Pulmonary M. scrofulaceum disease showing false-positive response of anti-GPL core IgA antibody. Infect Dis (Lond) 48(10):767-768, 2016 (IF = 3.404)
  3. Ogawara D, Fukuda M, Ueno S, Ohue Y, Takemoto S, Mizoguchi K, Nakatomi K, Nakamura Y, Obase Y, Honda T, Tsukamoto K, Ashizawa K, Oka M, Kohno S. Drug fever after cancer chemotherapy is most commonly observed on post treatment days 3-4. Supportive Care in Cancer 24(2):615-619, 2016 (IF = 3.603)
  4. Kasai T, Nakamura Y, Fukuda M, Kitazaki T, Nagashima S, Takatani H, Nakano H, Nakatomi K, Ikeda T, Yamaguchi H, Tsukamoto K, Oka M, Kohno S. Phase II study of S-1 for previously untreated elderly patients with advanced non-small cell lung cancer. Chemotherapy 61(2):93-98, 2016. 2016;61(2):93-8. doi: 10.1159/000441486. (IF = 2.544)
  5. Ogawara D, Fukuda M, Ueno S, Ohue Y, Takemoto S, Mizoguchi K, Nakatomi K, Nakamura Y, Obase Y, Honda T, Tsukamoto K, Ashizawa K, Oka M, Kohno S. Drug fever after cancer chemotherapy is most commonly observed on post treatment days 3-4. Supportive Care in Cancer 24(2):615-619, 2016 (IF = 2.649)
  6. Kasai T, Nakamura Y, Fukuda M, Kitazaki T, Nagashima S, Takatani H, Nakano H, Nakatomi K, Ikeda T, Yamaguchi H, Tsukamoto K, Oka M, Kohno S. Phase II study of S-1 for previously untreated elderly patients with advanced non-small cell lung cancer. Chemotherapy 61(2):93-98, 2016. (IF = 3.240)
  7. Nishimura T, Katoh S, Mori A, Ohmoto T, Saeki M, Hiroi T, Kaminuma O. Critical role of CD44 in antigen-induced Th2- but not Th17-mediated murine airway inflammation. Allergy International 65(Suppl):S59-61, 2016 (IF = 5.836)
2015年

  1. Kurose K, Ohue Y, Wada H, Iida S, Ishida T, Kojima T, Doi T, Suzuki S, Isobe M, Funakoshi T, Kakimi K, Nishikawa H, Udono H, Oka M, Ueda R, Nakayama E. Phase Ia study of FoxP3+ CD4 Treg depletion by infusion of a humanized anti-CCR4 antibody, KW-0761, in cancer patients. Clin Cancer Res 21(19):4327-4336, 2015 Oct 1. doi: 10.1158/1078-0432.CCR-15-0357. (IF = 12.531)
    Press Release by AACR, Am Asso for Cancer Res (Oct 1, 2015)
    http://www.aacr.org/Newsroom/Pages/News-Release-Detail.aspx?ItemID=766#.Vg0u19RKOK0
  2. Kurose K, Ohue Y, Sato E, Yamauchi A, Eikawa S, Isobe M, Nishio Y, Uenaka A, Oka M, Nakayama E. Increase in activated Treg in TIL in lung cancer and in vitro depletion of Treg by ADCC using an anti-human CCR4 mAb (KM2760). J Thorac Oncol 10(1):74-83, 2015 (IF = 15.609)
  3. Katoh S, Ikeda M, Shimizu H, Abe M, Ohue Y, Mouri K, Kobashi Y, Oka M. Increased galectin-9 concentration and number of CD4+Foxp3high+ cells in bronchoalveolar lavage fluid of patients with cryptogenic organizing pneumonia. Lung 193(5):683-689, 2015 (IF = 2.584)
  4. Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. PNAS 112(6):1815-1820, 2015 (IF = 11.205)
  5. Okita R, Wolf D, Yasuda K, Maeda A, Yukawa T, Saisho S, Shimizu K, Yamaguchi Y, Oka M, Nakayama E, Lundqvist A, Kiessling R, Seliger B, Nakata M. Contrasting effects of the cytotoxic anticancer drug Gemcitabine and the EGFR tyrosine kinase inhibitor Gefitinib on NK cell-mediated cytotoxicity via regulation of NKG2D ligand in non-small-cell lung cancer cells. PLoS One 10(10):e0139809, 2015 Oct 6. doi: 10.1371/journal.pone.0139809. (IF = 3.240)
  6. Eikawa S, Nishida M, Mizukami S, Yamazaki C, Nakayama E, Udono H. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. PNAS 112(6):1815-1820, 2015 (IF = 9.809)
  7. Okita R, Wolf D, Yasuda K, Maeda A, Yukawa T, Saisho S, Shimizu K, Yamaguchi Y, Oka M, Nakayama E, Lundqvist A, Kiessling R, Seliger B, Nakata M. Contrasting effects of the cytotoxic anticancer drug Gemcitabine and the EGFR tyrosine kinase inhibitor Gefitinib on NK cell-mediated cytotoxicity via regulation of NKG2D ligand in non-small-cell lung cancer cells. PLoS One 10(10):e0139809, 2015 (IF = 3.234)
2014年

  1. Ohue Y, Kurose K, Mizote Y, Matsumoto H, Nishio Y, Isobe M, Fukuda M, Uenaka A, Oka M, Nakayama E. Prolongation of overall survival in advanced lung adenocarcinoma patients with the XAGE1 (GAGED2a) antibody. Clin Cancer Res 20(19):5052-5063, 2014 (IF = 12.531)
    Selected in the "Highlight" section (Oct 1, 2014)
  2. Ohue Y, Wada H, Oka M, Nakayama E. Antibody response to cancer/testis (CT) antigens: A prognostic marker in cancer patients. OncoImmunology 3(11):e970032-33, 2014 (IF = 8.110)
  3. Pandey JP, Namboodiri AM, Ohue Y, Oka M, Nakayama E. Genetic variants of immunoglobulin gamma and kappa chains influence humoral immunity to the cancer-testis antigen XAGE-1b (GAGED2a) in patients with non-small cell lung cancer. Clin Exp Immunol 176(1):78-83, 2014 (IF = 4.330)
  4. Mizote, Y, Uenaka A, Isobe M, Wada H, Kakimi K, Saika T, Kita S, Koide Y, Oka M, Nakayama E. Production of NY-ESO-1 peptide/DRB1*08:03 tetramers and their use for ex vivo detection of CD4 T-cell responses in the vaccinated cancer patients. Vaccine 32(8):957-64, 2014 (IF = 3.641)
  5. Mizote Y, Wakamatsu K, Ito S, Uenaka A, Ohue Y, Kurose K, Isobe M, Ito A, Tamura Y, Honda H, Yamashita T, Nohara S, Oka M, Jimbow K, Nakayama E. TLR4 and NLRP3 inflammasome activation in monocytes by N-propionyl cysteaminylphenol-maleimid-dextran (NPCMD). J Dermatol Sci 73(3):209-15, 2014 (IF = 4.005)
  6. Wada H, Isobe M, Kakimi K, Mizote Y, Eikawa S, Sato E, Takigawa N, Kiura K, Tsuji K, Iwatsuki K, Yamasaki M, Miyata H, Matsushita H, Udono H, Seto Y, Yamada K, Nishikawa H, Pan L, Venhaus R, Doki Y, Oka M, Nakayama E. Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing NY-ESO-1 antigen. J Immunother 37(2):84-92, 2014 (IF = 4.110)
  7. Yamagishi T, Shimizu K, Ochi N, Yamane H, Irei I, Sadahira Y, Takigawa N, Oka M, Nakata M. Histological comparison between preoperative and surgical specimens of non-small cell lung cancer for distinguishing between “squamous” and “non-squamous” cell carcinoma. Diagn Pathol 9:103, 2014. Published online May 29, doi: 10.1186/1746-1596-9-103 (IF = 2.759)
  8. Katoh S, Ikeda M, Shimizu H, Mouri K, Obase Y, Kobashi Y, Fukushima K, Hirashima M, Oka M. Increased levels of plasma galectin-9 in patients with influenza virus infection. Tohoku J Exp Med 232(4):263-7, 2014 (IF = 1.848)
  9. Kobashi Y, Mouri K, Obase Y, Kato S, Oka M. Clinical application of T-SPOT.TB using pleural effusion as a diagnostic method for tuberculosis infection. Open J Respir Dis 4:64-72, 2014 (IF = 0)
2013年

  1. Eikawa S, Kakimi K, Isobe M, Kuzushima K, Luescher I, Ohue Y, Ikeuchi K, Uenaka A, Nishikawa H, Udono H, Oka M, Nakayama E. Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide. Int J Cancer 132(2):345-54, 2013 (IF = 7.396)
  2. Shimizu H, Obase Y, Katoh S, Mouri K, Kobashi Y, Oka M. Critical role of Interleukin-5 in the development of a mite antigen-induced chronic bronchial asthma model. Inflamm Res 62(10):911-917, 2013 (IF = 4.575)
  3. Kobashi Y, Mouri K, Obase Y, Katoh S, Oka M. Serological assay by use of glycopeptidolipid core antigen Mycobacterium avium complex. Scand J Infect Dis 45(4):241-9, 2013 (IF = 3.404)
  4. Katoh S, Shimizu H, Obase Y, Oomizu S, Niki T, Ikeda M, Mouri K, Kobashi Y, Hirashima M, Oka M. Preventive effect of galectin-9 on double-stranded RNA-induced airway hyperresponsiveness in an exacerbation model of mite antigen-induced asthma in mice. Exp Lung Research 39(10):453-62, 2013 (IF = 2.459)
  5. Obase Y, Ikeda M, Kurose K, Abe M, Shimizu H, Ohue Y, Mouri K, Katoh S, Kobashi Y, Oka M. Step-down of budesonide/formoterol in early stage of asthma treatment leads to insufficient anti-inflammatory effects. J Asthma 50(7):718-21, 2013 (IF = 2.515)
  7. Kobashi Y, Mouri K, Obase Y, Katoh S, Oka M. Clinical analysis of patients with pulmonary nontuberculous mycobacterial disease complicated by pneumothorax. Intern Med 52(22):2511-5, 2013 (IF = 1,271)
  8. Kobashi Y, Mouri K, Obase Y, Katoh S, Nakata M, Oka M. Mucoid impaction of the bronchi caused by Mycobacterium avium. Intern Med 52(13):1537-40, 2013 (IF = 1,271)
  9. Kobashi Y, Mouri K, Obase Y, Katoh S, Oka M. Clinical analysis of pulmonary nontuberculous mycobacterial disease diagnosed as coincidental pulmonary infection due to Mycobacterium species. Open J Respir Dis 3:107-12, 2013 (IF = 0)
  10. Matsumoto N, Katoh S, Yanagi S, Arimura Y, Tokojima M, Ueno M, Hirashima M, Nakazato M. A possible role of galectin-9 in the pulmonary fibrosis of patients with interstitial pneumonia. Lung 191(2):191-8, 2013 (IF = 2.584)
2012年

  1. Ohue Y, Eikawa S, Okazaki N, Mizote Y, Isobe M, Uenaka A, Fukuda M, Old LJ, Oka M, Nakayama E. Spontaneous antibody, and CD4 and CD8 T-cell responses against XAGE-1b (GAGED2a) in non-small cell lung cancer patients. Int J Cancer 131(5):E649-58, 2012 (IF = 7.396)
  2. Takatani H, Nakamura Y, Nagashima S, Soda H, Kinoshita A, Fukuda Mi, Fukuda Ma, Soejima Y, Kasai T, Nakatomi K, Iida T, Oka M, Tsukamoto K, Kohno S. Phase I and II trials of vinorelbine with carboplatin for patients 75 years of age or older with previously untreated non-small-cell lung cancer. Clin Lung Cancer 13(5):347-51, 2012 (IF = 4.785)
  3. Fukuda Mi, Nakamura Y, Kinoshita A, Soejima Y, Yamaguchi H, Ikeda T, Izumikawa K, Takatani H, Fukuda Ma, Soda H, Hayashi N, Tsukamoto K, Oka M, Kohno S. Phase II study of irinotecan and cisplatin with concurrent split-course radiotherapy in limited-disease small cell lung cancer. Cancer Chemother Pharmacol 70 (5):645-51, 2012 (IF = 3.333)
  4. Katoh S, Oomizu S, Niki T, Shimizu H, Obase Y, Korenaga M, Oka M, HIrashima M. Possible regulatory role of galectin-9 on Ascaris suum-induced eosinophilic lung inflammation in mice. Int Arch Allergy Immunol 158 (Suppl 1):58-65, 2012 (IF = 2.749)
  5. Kobashi Y, Abe M, Mouri K, Obase Y, Kato S, Oka M. Relationship between clinical efficacy for pulmonary MAC and drug-sensitivity test for isolated MAC in a recent 6-year period. J Infect Chemother 18(4):436-43, 2012 (IF = 2.211)
  6. Kobashi Y, Mouri K, Obase Y, Kato S, Oka M. Pulmonary Mycobacterium kyorinense disease showed clinical improvement following combined therapy with clarithromycin and levofloxacin. Intern Med 51(14):1923-6, 2012 (IF = 1,271)
  7. Kobashi Y, Abe M, Mouri K, Obase Y, Miyashita N, Oka M. Usefulness of tuberculin skin test and three interferon-gamma release assays for the differential diagnosis of pulmonary tuberculosis. Intern Med 51(10):1199-205, Epub 2012 (IF = 1,271)
  8. Kobashi Y, Abe M, Mouri K, Obase Y, Miyashita N, Oka M. Discussion regarding tuberculin skin tests and interferon-gamma release assays for the differential diagnosis of pulmonary tuberculosis. Intern Med 51(20):2999, Epub 2012 (IF = 1,271)
  9. Ohfuji T, Obase Y, Ikeda M, Obase K, Hayashida A, Okura H, Kobashi Y, Yoshida K, Oka M. A case of platypnea orthodeoxia syndrome: a persistent history taking was the key to diagnose. Intern Med 51(13):1701-4, Epub 2012 (IF = 1,271)
2011年

  1. Katoh S, Kaminuma O, Hiroi T, Mori A, Ohtomo T, Maeda S, Shimizu H, Obase Y, Mak TW, Oka M. CD44 is critical for airway accumulation of antigen-specific Th2 cells, but not Th1 cells, induced by antigen challenge in mice. Eur J Immunol 41(11):3198-207, 2011 (IF = 5.532)
  2. Nakamura Y, Soda H, Oka M, Kinoshita A, Fukuda Mi, Fukuda Ma, Takatani H, Nagashima S, Soejima Y, Kasai T, Nakatomi K, Doi S, Masuda N, Tsukamoto K, Kohno S, for the Nagasaki Thoracic Oncology Group. Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small-cell lung cancer: association of UGT1A1*6 and UGT1A1*27 with severe neutropenia. J Thorac Oncol 6(1):121-7, 2011 (IF = 15.609)
  3. Kakimi K, Isobe M, Uenaka A, Wada H, Sato E, Doki Y, Nakajima J, Seto Y, Yamatsuji T, Naomoto Y, Shiraishi K, Takigawa N, Kiura K, Tsuji K, Iwatsuki K, Oka M, Pan L, Hoffman EW, Old LJ, Nakayama E. A phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing NY-ESO-1 antigen. Int J Cancer 129(12):2836-46, 2011 (IF = 7.396)
  4. Shimizu H, Obase Y, Ikeda M, Kurose K, Abe M, Mouri K, Katoh S, Miyashita N, Kobashi Y, Oka M. Stability of sealed-bag samples for off-line measurement of fractional exhaled nitric oxide. Annals of Allergy, Asthma & Immunology 106(5):378-80, 2011 (IF = 6.347)
  5. Obase Y, Mouri K, Ohue Y, Kobashi Y, Kawahara K, Oka M. Nutritional deficits in elderly smokers with respiratory symptoms that do not fulfill the criteria for COPD. Int J COPD 6:1-5, 2011 (IF = 3.355)
  6. Ogino K, Obase Y, Takahashi N, Shimizu H, Takigawa T, Wang DH, Ouchi K, Oka M. High serum arginase I levels in asthma: its correlation with high-sensitivity C-reactive protein. J Asthma 48(1):1-7, 2011 (IF = 2.515)
  7. Miyashita N, Kawai Y, Yamaguchi T, Ouchi K, Oka M; Atypical Pathogen Study Group. Clinical potential of diagnostic methods for the rapid diagnosis of Mycoplasma pneumoniae pneumonia in adults. Eur J Clin Microbiol Infect Dis 30(3):439-46, 2011 (IF = 2.837)
  8. Miyashita N, Maruyama T, Kobayashi T, Kobayashi H, Taguchi O, Kawai Y, Yamaguchi T, Ouchi K, Oka M. Community-acquired macrolide-resistant Mycoplasma pneumoniae pneumonia in patients more than 18 years of age. J Infect Chemother 17(1):114-8, 2011 (IF = 2.211)
  9. Kobashi Y, Mouri K, Obase Y, Miyashita N, Nakanaga K, Oka M. Pulmonary Mycobacterium massiliense disease with septicemia during immunosuppressive treatment. Intern Med 50(9):1069-73, Epub 2011 (IF = 1,271)
  10. Abe M, Kobashi Y, Mouri K, Obase Y, Miyashita N, Nakata M, Oka M. Solitary pulmonary nodule due to Mycobacterium kansasii. Intern Med 50(7):775-8, Epub 2011 (IF = 1,271)
  11. Ogino K, Takahashi N, Obase Y, Wang Da-Hong, Takigawa T. High serum arginase I levels in asthma: its correlation with high sensitivity C-reactive protein. Free Radical Res 45(2):147-55, 2011 (IF = 4.148)
  12. Miyashita N, Kawai Y, Yamaguchi T, Ouchi K, Kurose K, Oka M. Outbreak of pertussis in a university laboratory. Intern Med 50(8):879-85, Epub 2011 (IF = 1,271)
2010年

  1. Eikawa S, Ohue Y, Kitaoka K, Aji T, Uenaka A, Oka M, Nakayama E. Enrichment of Foxp3+ CD4 Tregs in migrated T-cells to IL-6- and IL-8-expressing tumors through predominant induction of CXCR1 by IL-6. J Immunol 185(11):6734-40, 2010 (IF = 5.422)
  2. Nakamura Y, Sano K, Soda H, Takatani H, Fukuda M, Nagashima S, Hayashi T, Oka M, Tsukamoto K, Kohno S. Pharmacokinetics of gefitinib predicts antitumor activity for advanced non-small cell lung cancer. J Thorac Oncol 5(9):1404-9, 2010 (IF = 15.609)
  3. Shimizu K, Nakata M, Maeda A, Yukawa T, Hirami Y, Tanemoto K, Oka M. Induction chemoradiation therapy with cisplatin plus irinotecan followed by surgical resection for superior sulcus tumor. Ann Thorac Cardiovasc Surg 16(5):326-30, 2010 (IF = 4.101)
  4. Katoh S, Maeda S, Fukuoka H, Wada T, Moriya S, Mori A, Yamaguchi K, Senda S, Miyagi T. A crucial role of sialidase Neu1 in hyaluronan receptor function of CD44 in T helper type 2-mediated airway inflammation of murine acute asthmatic model. Clin Exp Immunol 161:233-41, 2010 (IF = 4.330)
  5. Katoh S, Nobumoto A, Matsumoto N, Matsumoto K, Ehara N, Niki T, Inada H, Nishi N, Yamauchi A, Fukushima K, Hirashima M. Involvement of galectin-9 in lung eosinophilia in patients with eosinophilic pneumonia. Int Arch Allergy Immunol 153:294-302, 2010 (IF = 2.749)
  6. Kobashi Y, Abe M, Mouri K, Obase Y, Miyashita N, Oka M. Clinical usefulness of combination chemotherapy for pulmonary Mycobacterium avium complex disease. J Infect, Nov 19, 2010 [Epub ahead of print] (IF = 4.126)
  7. Kobashi Y, Abe M, Mouri K, Obase Y, Miyashita N, Oka M. Rapid diagnosis of tuberculous pericarditis by ELISPOT assay. Scand J Infect Dis 42(9):712-5, 2010 (IF = 3.404)
  8. Kobashi Y, Shimizu H, Ohue Y, Mouri K, Obase Y, Miyashita N, Oka M. Comparison of T-cell interferon-gamma release assays for Mycobacterium tuberculosis-specific antigens in patients with active and latent tuberculosis. Lung 188(4):283-7, 2010 (IF = 2.584)
  9. Kobashi Y, Abe T, Shigeto E, Yano S, Kuraoka T, Oka M. Desensitization therapy for allergic reactions to antituberculous drugs. Intern Med 49(21):2297-301, 2010 (IF = 1,271)
  10. Miyashita N, Oka M; Atypical Pathogen Study Group, Kawai Y, Yamaguchi T, Ouchi K. Macrolide-resistant Mycoplasma pneumoniae in adults with community-acquired pneumonia. Int J Antimicrob Agents 36(4):384-5, 2010 (IF = 3.032)
  11. Miyashita N, Kawai Y, Yamaguchi T, Ouchi K, Kobashi Y, Oka M. Evaluation of false-positive reaction with ELISA for the detection of Chlamydophila pneumoniae-specific IgM antibody in adults. Jpn J Infect Dis 63(2):150-1, 2010 (IF = 1.259)
  12. Mizote Y, Taniguchi T, Tanaka K, Isobe M, Wada H, Saika T, Kita S, Koide Y, Uenaka A, Nakayama E. Three novel NY-ESO-1 epitopes bound to DRB1*0803, DQB1*0401 and DRB1*0901 recognized by CD4 T cells from CHP-NY-ESO-1-vaccinated patients. Vaccine 28(32):5338-46, 2010 (IF = 3.641)
  13. Arikawa T, Saita N, Oomizu S, Ueno M, Matsukawa A, Katoh S, Kojima K, Nagahara K, Miyake M, Yamauchi A, Kohrogi H, Hirashima M. Galectin-9 expands immunosuppressive macrophages to ameliorate T-cell-mediated lung inflammation. Eur J Immunol 40(2):548-58, 2010 (IF = 5.532)
  14. Motodate S, Kobayashi T, Fujii M, Mochida T, Kusakabe T, Katoh S, Akita H, Kato K. Synthesis of β-methoxyacrylate natural products based on box-pdп-catalyzed intermolecular methoxycarbonylation of alkynoles. Chem Asian J 5(10):2221-30, 2010 (IF = 4.373)
2009年

  1. Kobashi Y, Sugiu T, Shimizu H, Ohue Y, Mouri K, Obase Y, Miyashita N, Oka M. Clinical evaluation of the T-SPOT.TB test for patients with indeterminate results on the QuantiFERON TB-2G test. Intern Med 48(3):137-142, 2009
  2. Kobashi Y, Mouri K, Yagi S, Obase Y, Miyashita N, Oka M. Transitional changes in T-cell responses to Mycobacterium tuberculosis-specific antigens during treatment. J Infect 58(3):197-204, 2009
  3. Kobashi Y, Mouri K, Yagi S, Obase Y, Miyashita N, Oka M. Clinical utility of a T cell-based assay in the diagnosis of extrapulmonary tuberculosis. Respirology 14(2):276-281, 2009
  4. Kobashi Y, Shimizu H, Mouri K, Obase Y, Miyashita N, Oka M. Rapid diagnosis of tuberculous pleuritis by a T-cell interferon-gamma release assay. Scand J Infect Dis 41(3):232-236, 2009
  5. Kobashi Y, Sugiu T, Mouri K, Obase Y, Miyashita N, Oka M. Indeterminate results of QuantiFERON TB-2G test performed in routine clinical practice. Eur Respir J 33(4):812-815, 2009
  6. Kobashi Y, Mouri K, Miyashita N, Oka M. Clinical usefulness of QuantiFERON TB-2G test for the early diagnosis of pulmonary Mycobacterium kansasii disease. Jpn J Infect Dis 62(3):239-241, 2009
  7. Kobashi Y, Shimizu H, Ohue Y, Mouri K, Obase Y, Miyashita N, Oka M. False negative results of QuantiFERON TB-2G test in patients with active tuberculosis. Jpn J Infect Dis 62(4):300-302, 2009
  8. Kobashi Y, Mouri K, Miyashita N, Okimoto N, Matsushima T, Kageoka T, Oka M. QuantiFERON TB-2G test for patients with active tuberculosis stratified by age groups. Scand J Infect Dis 41(11-12):841-846, 2009
  9. Kobashi Y, Shimizu H, Mouri K, Obase Y, Miyashita N, Oka M. Clinical evaluation of QuantiFERON TB-2G test in patients with healed pulmonary tuberculosis. J Infect Chemother 15(5):288-292, 2009
  10. Kobashi Y, Shimizu H, Mouri K, Irei T, Oka M. Clinical usefulness of fluoro-2-deoxy-D-glucose PET in a case with multiple bone metastases of carcinoid tumor after ten years. Intern Med 48(21):1919-1923, 2009
  11. Kobashi Y, Mouri K, Yagi S, Obase Y, Miyashita N, Okimoto N, Matsushima T, Kageoka T, Oka M. Clinical evaluation of the QuantiFERON-TB Gold test in patients with non-tuberculous mycobacterial disease. Int J Tuberc Lung Dis 13(11):1422-1426, 2009
  12. Miyashita N, Sugiu T, Kawai Y, Oda K, Yamaguchi T, Ouchi K, Kobashi Y, Oka M. Radiographic features of Mycoplasma pneumoniae pneumonia: differential diagnosis and performance timing. BMC Med Imaging 29;9:7, 2009
  13. Obase Y, Rytilä P, Metso T, Pelkonen AS, Tervahartiala T, Turpeinen M, Mäkelä M, Saarialho-Kere U, Selroos O, Sorsa T, Haahtela T. Effects of Inhaled Corticosteroids on Metalloproteinase-8 and Tissue Inhibitor of Metalloproteinase-1 in the Airways of Asthmatic Children. Int Arch Allergy Immunol 29;151(3):247-254, 2009
  14. Kawai Y, Miyashita N, Kishi F, Tabuchi M, Oda K, Yamaguchi T, Kawasaki K, Yamazaki T, Ouchi K. Development and evaluation of a loop-mediated isothermal amplification method for the rapid detection of Chlamydophila pneumoniae. Eur J Clin Microbiol Infect Dis 28(7):801-5, 2009
  15. Hida A, Yagi S, Obase Y, Nishimura H, Akiyama T, Irei I, Hamazaki S, Oka M, Sadahira Y. Rosai-Dorfman disease presenting as a solitary mediastinal mass. Pathol Int 59(4):265-268, 2009
  16. Domae S, Nakamura Y, Nakamura Y, Uenaka A, Wada H, Nakata M, Oka M, Kishimoto K, Tsukamoto G, Yoshihama Y, Matsuoka J, Gochi A, Kohno S, Saika T, Sasaki A, Nakayama E, Ono T. Identification of CCDC62-2 as a novel cancer/testis antigen and its immunogenicity. Int J Cancer 124(10):2347-52, 2009
  17. Fukuda M, Nakamura Y, Kasai T, Nagashima S, Nakatomi K, Doi S, Nakano H, Takatani H, Fukuda M, Kinoshita A, Soda H, Tsukamoto K, Oka M, Kohno S; Nagasaki Thoracic Oncology Group. A Phase I study of amrubicin and carboplatin for previously untreated patients with extensive-disease small-cell lung cancer. J Thorac Oncol 4(6):741-745, 2009
  18. Tabuchi M, Kawai Y, Nishie-Fujita M, Akada R, Izumi T, Yanatori I, Miyashita N, Ouchi K, Kishi F. Development of a novel functional high-throughput screening system for pathogen effectors in the yeast Saccharomyces cerevisiae. Biosci Biotechnol Biochem 73(10):2261-2267, 2009
  19. Morinaga Y, Yanagihara K, Miyashita N, Seki M, Izumikawa K, Kakeya H, Yamamoto Y, Mukae H, Yamada Y, Kohno S, Kamihira S. Azithromycin, clarithromycin and telithromycin inhibit MUC5AC induction by Chlamydophila pneumoniae in airway epithelial cells. Pulm Pharmacol Ther 22(6):580-586, 2009
  20. Miyashita N, Kawai Y, Yamaguchi T, Ouchi K, Kobashi Y, Oka M: Evaluation of false-positive reaction with ELISA for the detection of Chlamydophila pneumoniae-specific IgM antibody in adults. Jpn J Infect Dis (in press)
2008年

  1. Kobashi Y, Mouri K, Yagi S, Obase Y, Miyashita N, Okimoto N, Matsushima T, Kageoka T, Oka M. Clinical utility of the QuantiFERON TB-2G test for elderly patients with active tuberculosis. Chest 133:1196-1202, 2008
  2. Kobashi Y, Sugiu T, Mouri K, Irei T, Nakata M, Oka M. Clinicopathological analysis of multifocal micronodular pneumocyte hyperplasia associated with tuberous sclerosis in Japan. Respirology 13(7):1076-1081, 2008
  3. Kobashi Y, Mouri K, Fukuda M, Yoshida K, Miyashita N, Oka M. Transitional change in the clinical features of pulmonary tuberculosis. Respiration 75(3):304-309, 2008
  4. Kobashi Y, Shimizu H, Mouri K, Obase Y, Miyashita N, Oka M. Rapid diagnosis of tuberculous pleuritis by a T-cell interferon-gamma release assay. Scand J Infect Dis 23:1-5, 2008
  5. Kobashi Y, Mouri K, Yagi S, Obase Y, Miyashita N, Okimoto N, Matsushima T, Kageoka T, Oka M. Clinical evaluation for diagnosis active TB disease and transitional change of two commercial blood tests. Scand J Infect Dis 40:629-634, 2008
  6. Kobashi Y, Sugiu T, Ohue Y, Mouri K, Obase Y, Miyashita N, Oka M. Long-term follow-up of the QuantiFERON TB-2G test for active tuberculosis disease. Intern Med 47(22):1957-1961, 2008
  7. Kobashi Y, Mouri K, Yagi S, Obase Y, Fukuda M, Miyashita N, Oka M. Usefulness of the QuantiFERON TB-2G test for the differential diagnosis of pulmonary tuberculosis. Intern Med 47:237-243, 2008
  8. Kobashi Y, Sugiu T, Mouri K, Irei T, Nakata M, Oka M. Multifocal micronodular pneumocyte hyperplasia associated with tuberous sclerosis: differentiation from multiple atypical adenomatous hyperplasia. Jpn J Clin Oncol 38:451-454, 2008
  9. Kobashi Y, Mouri K, Yagi S, Obase Y, Oka M. Clinical analysis of cases of empyema due to Streptococcus milleri group. Jpn J Infect Dis 61(6):484-486, 2008
  10. Miyashita N, Ouchi K, Kawasaki K, Komura H, Kawai Y, Tsumura N, Bannai H, Iwata S, Oka M. Comparison of serological tests for detection of immunoglobulin M antibodies to Chlamydophila pneumoniae. Respirology 13(3):427-31, 2008
  11. Miyashita N, Ouchi K, Kawasaki K, Komura H, Kawai Y, Obase Y, Kobashi Y, Oka M. Evaluation of enzyme-linked immunosorbent assay for Chlamydophila pneumoniae - specific immunoglobulin M in acute respiratory tract infection. Respirology 13(2):299-302, 2008
  12. Miyashita N, Ouchi K, Kishi F, Tabuchi M, Tsumura N, Bannai H, Iwata S, Tanaka T, Oka M. Rapid and simple diagnosis of Chlamydophila pneumoniae pneumonia by an immunochromatographic test for detection of immunoglobulin M antibodies. Clin Vaccine Immunol 15(7):1128-31, 2008
  13. Miyashita N, Shimizu H, Ouchi K, Kawasaki K, Kawai Y, Obase Y, Kobashi Y, Oka M. Assessment of the usefulness of sputum Gram stain and culture for diagnosis of community-acquired pneumonia requiring hospitalization. Med Sci Monit 14(4):CR171-176, 2008
  14. Miyashita N, Ouchi K, Kawasaki K, Oda K, Kawai Y, Shimizu H, Kobashi Y, Oka M. Mycoplasma pneumoniae pneumonia in the elderly. Med Sci Monit 14(8):CR387-391, 2008
  15. Yagi S, Miyashita N, Fukuda M, Obase Y, Yoshida K, Miyauchi A, Kawasaki K, Soda H, Oka M. Pulmonary mucormycosis (Cunninghamella bertholletiae) with cavitation diagnosed using ultra-thin fibre-optic bronchoscopy. Respirology 13(2):312-314, 2008
  16. Shimizu H, Miyashita N, Obase Y, Sugiu T, Ohue Y, Mouri K, Yagi S, Kobashi Y, Oka M. An asymptomatic case of pulmonary cryptococcosis with endobronchial polypoid lesions and bilateral infiltrative shadow. J Infect Chemother 14(4):315-318, 2008
  17. Tomonaga N, Nakamura Y, Soda H, Nagasgima S, Nakano H, Kinoshita A, Fukuda Mi, Fukuda Ma, Takatani H, Soejima Y, Oka M, Kohno S, for the Nagasaki Thoracic Oncology Group. Phase I study of vinorelbine and irinotecan in previously untreated patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol 62(1):43-49, 2008
  18. Nakamura Y, Satake K, Sano K, Ito A, Yoshikawa M, Ikegami Y, Yoshida H, Nakano H, Oka M, Sawada S, Soda H, Kohno S. Gefitinib increases serum concentrations of oral irinotecan and SN-38 without increasing the biliary concentration of SN-38 in rats. Chemotherapy 54(6):485-491, 2008
  19. Akamine S, Nakamura Y, Oka T, Soda H, Taniguchi H, Fukuda M, Minami H, Nagashima S, Ashizawa K, Goya T, Oka M, Kohno S, Tagawa T, Nagayasu T, for the Nagasaki Thoracic Oncology Group. Induction chemotherapy with cisplatin, vinorelbine, and mitomycin-C followed by surgery for patients with pathologic N2 non-small-cell lung cancer. Clin Lung Cancer 9(1):44-50, 2008
  20. Niki Y, Yoshida K, Miyashita N, Oka M, Hara H, Kishimoto M, Okimoto N, Kawanishi M, Uno M, Kamao T, Yoneyama H, Nakamura J, Kimura M, Watanabe M, Tanimukai T, Moriya O, Matsushima T. Evaluation of clinical dosage of gatifloxacin for respiratory tract infections in elderly patients based on pharmacokinetics/pharmacodynamics (PK/PD). J Infect Chemother 14(4):296-304, 2008
  21. Louhelainen N, Rytilä P, Obase Y, Mäkelä M, Haahtela T, Kinnula VL, Pelkonen A. The value of sputum 8-isoprostane in detecting oxidative stress in mild asthma. J Asthma 45(2):149-154, 2008
  22. Kobashi Y, Mouri K, Yagi S, Obase Y, Miyashita N, Oka M. Transitional changes in T-cell responses to Mycobacterium tuberculosis-specific antigens during treatment. J Infect, 2008 (in press)
  23. Domae S, Nakamura Yo, Nakamura Yu, Uenaka A, Wada H, Nakata M, Oka M, Kishimoto K, Tsukamoto G, Yoshihama Y, Matsuoka J, Gochi A, Kohno S, Saika T, Sasaki A, Nakayama E, Ono T. Identification of CCDC62-2 as a novel cancer/testis antigen and its immunogenicity. Int J Cancer, 2008 (in press)
  24. Fukuda M, Nakamura Y, Kasai T, Nagashima S, Nakatomi K, Doi S, Nakano H, Takatani H, Fukuda Ma, Kinoshita A, Soda H, Tsukamoto K, Oka M, Kohno S, for the Nagasaki Thoracic Oncology Group. A Phase I study of amrubicin and carboplatin for previously untreated patients with extensive-disease small-cell lung cancer. J Thorac Oncol, 2008 (in press)
  25. Hida A, Yagi S, Obase Y, Nishimura H, Akiyama T, Irei I, Hamazaki S, Oka M, Sadahira Y. Rosai-Dorfman disease presenting as a solitary mediastinal mass. Pathol Int, 2008 (in press)

2007年

  1. Fukuda M, Soda H, Fukuda Ma, Kinoshita A, Nakamura Y, Nagashima S, Takatani H, Kasai T, Kitazaki T, Tsurutani J, Ichiki M, Hayashi N, Tsukamoto K, Kohno S, Oka M, for the Nagasaki Thoracic Oncology Group. Irinotecan and cisplatin with concurrent split-course radiotherapy in locally advanced non-small cell lung cancer: a multi-institutional phase II study. Cancer 110:606-613, 2007（肺がん）
  2. Fukuda M, Obase Y, Miyashita N, Kobashi Y, Mohri K, Ueno S, Hayama M, Shimizu K, Nishimura H, Nakata M, Oka M. Paclitaxel and cisplatin with concurrent radiotherapy followed by surgery in locally advanced thymic carcinoma. Anticancer Res 27:1601-1604, 2007（肺がん）
  3. Kobashi Y, Mouri K, Yagi S, Obase Y, Miyashita N, Okimoto N, Matsushima T, Oka M. Clinical features of immunocompromised and nonimmunocompromised patients with pulmonary tuberculosis. J Infect Chemother 13:405-410, 2007（感染症）
  4. Kobashi Y, Mouri K, Obase Y, Fukuda M, Miyashita N, Oka M. Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients. Eur Respir J 30:945-950, 2007（感染症）
  5. Kobashi Y, Obase Y, Fukuda M, Miyashita N, Fujii M, Oka M. Usefulness of QuantiFERON TB-2G, a diagnostic method for latent tuberculosis infection, in a contact investigation of health care workers. Intern Med 46:1543-1549, 2007（感染症）
  6. Kobashi Y, Mouri K, Fukuda M, Yoshida K, Oka M. The usefulness of bronchoscopy for the diagnosis of pulmonary tuberculosis. J Bronchol 14:22-25, 2007（感染症）
  7. Kobashi Y, Matsushima T, Oka M. A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease. Respir Med 101:130-138, 2007（感染症）
  8. Kobashi Y, Fukuda M, Yoshida K, Oka M. An indeterminate QuantiFERON TB-2G response for miliary tuberculosis, due to severe pancytopenia. J Infect Chemother 13:414-417, 2007（感染症）
  9. Kobashi Y, Yoshida K, Miyashita N, Niki Y, Matsushima T. Evaluating the use of a Streptococcus pneumoniae urinary antigen detection kit for the management of community-acquired pneumonia in Japan. Respiration 74:387-393, 2007（感染症）
  10. Kobashi Y, Matsushima T. The microbiological and clinical effects of combined therapy according to guidelines on the treatment of pulmonary Mycobacterium avium complex disease in Japan-including a follow-up study. Respiration 74:394-400, 2007（感染症）
  11. Miyashita N, Obase Y, Fukuda M, Shoji H, Yoshida K, Ouchi K, >Oka M. Evaluation of the diagnostic usefulness of real-time PCR for detection of Chlamydophila pneumoniae in acute respiratory infections. J Infect Chemother 13:183-187, 2007（感染症）
  12. Miyashita N, Obase Y, Ouchi K, Kawasaki K, Kawai Y, Kobashi Y, Oka M. Clinical features of severe Mycoplasma pneumoniae pneumonia in adults admitted to an intensive care unit. J Med Microbiol 56:1625-1629, 2007（感染症）
  13. Mohri K, Miyashita N, Obase Y, Fukuda M, Ohue Y, Ueno S, Yagi S, Kobashi Y, Soda H, Oka M. Pulmonary alveolar proteinosis with bilateral ground-glass opacities localized in subpleural areas. Journal of the Japan Society for Respiratory Endoscopy 29:275-278, 2007（気管支鏡、肺胞蛋白症）
  14. Ishida T, Miyashita N, Nakahama C. Clinical differentiation of atypical pneumonia using Japanese guidelines. Respirology 12:104-110, 2007（感染症）
  15. Takatani H, Soda H, Nakamura Y, Kinoshita A, Fukuda Ma, Nagashima S, Fukuda Mi, Soejima Y, Nakano H, Oka M, Kohno S, for the Nagasaki Thoracic Oncology Group. Phase I study of irinotecan and gemcitabine in previously untreated patients with advanced non-small cell lung cancer. Jpn J Clin Oncol 37:353-357, 2007（肺がん）
  16. Tanaka R, Matsuura H, Kobashi Y, Fujimoto W. Clinical utility of an interferon-γ-based assay for mycobacterial detection in papulonecrotic tuberculid. Br J Dermatol 156:169-171, 2007（感染症）
  17. Tomonaga N, Nakamura Y, Soda H, Nagashima S, Nakano H, Kinoshita A, Fukuda Ma, Fukuda Mi, Takatani H, Soejima Y, Oka M, Kohno S, for the Nagasaki Thoracic Oncology Group. Phase I study of vinorelbine and irinotecan in previously untreated patients with advanced non-small cell lung cancer. Cancer Chemother Pharmacol, August 24, Epub 2007（肺がん）

2006年

  1. Fukuda M, Soda H, Soejima Y, Fukuda Ma, Kinoshita A, Takatani H, Kasai T, Nagashima S, Kawabata S, Doi S, Kohno S, Oka M. A phase I trial of carboplatin and etoposide for elderly (_ 75 year-old) patients with small-cell lung cancer. Cancer Chemother Pharmacol 58:601-606, 2006（肺がん）
  2. Fukuda M, Obase Y, Miyashita N, Shibata D, Yoshida K, Mori Y, Mouri K, Yoshida K, Kobashi Y, Niki Y, Oka M. Both bronchial and vascular stenting followed by chemoradiotherapy for locally advanced non-small cell lung cancer. Anticancer Res 26:565-568, 2006（肺がん）
  3. Kobashi Y, Obase Y, Fukuda M, Yoshida K, Miyashita N, Oka M. Clinical reevaluation of the QuantiFERON TB-2G test as a diagnostic method for differentiating active tuberculosis from nontuberculous mycobacteriosis. Clin Infec Dis 43:1540-1546, 2006（感染症）
  4. Kobashi Y, Fukuda M, Nakata M, Irei T, Oka M. Inflammatory pseudotumor of the lung: clinicopathological analysis in seven adult patients. Int J Clin Oncol 11:461-466, 2006（肺腫瘍）
  5. Kobashi Y, Yoshida K, Niki Y, Oka M. Sibling cases of Mycobacterium avium complex disease associated with hematological disease. J Infect Chemother 12:331-334, 2006（感染症）
  6. Kobashi Y, Fukuda M, Yoshida K, Miyashita N, Oka M. Chronic necrotizing pulmonary aspergillosis as a complication of pulmonary Mycobacterium avium complex disease. Respirology 11:809-813, 2006（感染症）
  7. Kobashi Y, Fukuda M, Yoshida K, Miyashita N, Oka M. Pulmonary Mycobacterium intracellulare disease with a solitary pulmonary nodule detected at the onset of pneumothorax. J Infect Chemother 12:203-206, 2006（感染症）
  8. Kobashi Y, Yoshida K, Miyashita N, Oka M. Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates. J Infect Chemother 12:195-202, 2006（感染症）
  9. Kobashi Y, Fukuda M, Yoshida K, Miyashita N, Oka M. Four cases of pulmonary Mycobacterium avium intracellulare complex presenting as a solitary pulmonary nodule and a review of other cases in Japan. Respirology 11:317-321, 2006（感染症）
  10. Kobashi Y, Fukuda M, Yoshida K, Miyashita N, Oka M. Synchronus presentation of early-stage small cell carcinoma and adenocarcinoma in the same lung lobe. Intern Med 45:287-291, 2006（肺がん）
  11. Miyashita N, Obase Y, Fukuda M, Shoji H, Mouri K, Yagi S, Yoshida K, Ouchi K, Oka M. Evaluation of serological tests detecting Chlamydophila pneumonia-specific immunoglobulin M antibody. Intern Med 45:1127-1131, 2006（感染症）
  12. Miyashita N, Matsushima T, Oka M. The JRS guidelines for the management of community-acquired pneumonia in adults: an update and new recommendations. Intern Med 45:419-428, 2006（感染症）
  13. Kinoshita A, Fukuda M, Soda H, Nagashima S, Fukuda M, Takatani H, Kuba M, Nakamura Y, Tsurutani J, Kohno S, Oka M. Phase II study of irinotecan combined with carboplatin in previously untreated small-cell lung cancer. Br J Cancer 94:1267-1271, 2006（肺がん）
  14. Nagashima S, Soda H, Oka M, Kitazaki T, Shiozawa K, Nakamura Y, Takemura M, Yabuuchi H, Fukuda M, Tsukamoto K, Kohno S. BCRP/ABCG2 levels account for the resistance to topoisomerase I inhibitors and reversal effects by gefitinib in non-small cell lung cancer. Cancer Chemother Pharmacol 58:594-600, 2006（肺がん）
  15. Suenaga M, Yamaguchi A, Soda H, Orihara K, Tokito Y, Sakaki Y, Umehara M, Terashi K, Kawamata N, Oka M, Kohno S, Tei C. Antiproliferative effects of gefitinib are associated with suppression of E2F-1 expression and telomerase activity. Anticancer Res 26:3387-3392, 2006（肺がん）

2005年

  1. Miyashita N, Fukano H, Mouri K, Fukuda M, Yoshida K, Kobashi Y, Niki Y, Oka M. Community-acquired pneumonia in Japan: a prospective ambulatory and hospitalized patient study. J Med Microbiol 54:395-400, 2005（感染症）
  2. Miyashita N, Ouchi K, Shoji H, Obase Y, Fukuda M, Yoshida K, Niki Y, Oka M. Outbreak of infection in long-term care facilities and an affiliated hospital. J Med Microbiol 54:1243-1247, 2005（感染症）
  3. Miyashita N, Fukano H, Mouri K, Fukuda M, Yoshida K, Kobashi Y, Niki Y, Oka M. Self-limiting pneumonia due to Chlamydia pneumoniae. Intern Med 44:870-874, 2005（感染症）
  4. Kobashi Y, Fukuda M, Nakata M, Oka M. Coexistence of metastatic lung cancer and pulmonary tuberculosis diagnosed in the same cavity. Int J Clin Oncol l10:366-370, 2005（肺がん）
  5. Kobashi Y, Fukuda M, Yoshida K, Miyashita N, Niki Y, Oka M. Lung adenocarcinoma required the differentiation for Wegener granulomatosis. Kawasaki Med J 30:79-85, 2005（肺がん）
  6. Kobashi Y, Yoshida K, Miyashita N, Niki Y, Oka M. Infectious bulla of the lung caused by Mycobacterium intracellulare. J Infect Chemother 11:293-296, 2005（感染症）
  7. Obase Y, Matsuse H, Shimoda T, Haahtela T, Kohno S. Pathogenesis and management of aspirin-intolerant asthma. Treat Respir Med 4:325-336, 2005（喘息）
  8. Nakamura Y, Oka M, Soda H, Shiozawa K, Yoshikawa M, Itoh A, Ikegami Y, Tsurutani J, Nakatomi K, Kitazaki T, Doi S, Yoshida H, Kohno S. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance. Cancer Res 65:1541-1546, 2005（肺がん）
  9. Kitazaki T, Oka M, Nakamura Y, Tsurutani J, Doi S, Yasunaga M, Takemura M, Yabuuchi H, Soda H, Kohno S. Gefitinib, an EGFR tyrosine kinase inhibitor, directly inhibits the function of P-glycoprotein in multidrug resistant cancer cells. Lung Cancer 49:337-347, 2005（肺がん）
  10. Machida I, Matsuse H, Kondo Y, Kawano T, Saeki S, Tomari S, Obase Y, Fukushima C, Kohno S. Effects of various anti-asthmatic agents on mite allergen-pulsed murine bone marrow-derived dendritic cells. Clin Exp Allergy 35:884-888, 2005（喘息）
  11. Tsuchida T, Matsuse H, Machida I, Kondo Y, Saeki S, Tomari S, Obase Y, Matsuo N, Shimoda T, Kohno S. Evaluation of theophylline or pranlukast, a cysteinyl leukotriene receptor 1 antagonist, as add-on therapy in uncontrolled asthmatic patients with a medium dose of inhaled corticosteroids. Allergy Asthma Proc 26:287-291, 2005（喘息）
  12. Fukushima C, Matsuse H, Hishikawa Y, Kondo Y, Machida I, Saeki S, Kawano T, Tomari S, Obase Y, Shimoda T, Koji T, Kohno S. Pranlukast, a leukotriene receptor antagonist, inhibits interleukin-5 production via a mechanism distinct from leukotriene receptor antagonism. Int Arch Allergy Immunol 136:165-172, 2005（喘息）
  13. Fukushima C, Matsuse H, Hishikawa Y, Kondo Y, Machida I, Saeki S, Kawano T, Tomari S, Obase Y, Shimoda T, Koji T, Kohno S. Pranlukast, a leukotriene receptor antagonist, inhibits interleukin-5 production via a mechanism distinct from leukotriene receptor antagonism. Int Arch Allergy Immunol 136:165-72, 2005（喘息）